Abstract
Chronic pain is a widespread healthcare problem affecting not only the patient but in many ways all the society. Chronic pain is a disease itself that endures for a long period of time and it is resistant to the majority of medical treatments that provide modest improvements in pain and minimum improvements in physical and emotional functioning. More co-existing chronic pain conditions may be present in the same individual (patient). The α9α10 nicotinic acetylcholine receptor (nAChR) may be a potential target in the pathophysiology of chronic pain, as well in the development of breast and lung cancers. α-conotoxins (α-CNT) are small peptides used offensively by carnivorous marine snails known as Conus that target nAChR. Among α-CNT there are potent and selective antagonists of α9α10 nAChR such as RgIA and Vc1.1 that produces both acute and long lasting analgesia. Moreover, these peptides accelerate the recovery of nerve function after injury, likely through immune/inflammatory-mediated mechanisms. We review the background, findings, implications and problems in using compounds that act on α9α10 nAChR.
Keywords: Chronic pain, α9α10 nAChR, α-conotoxins, pathophysiology, RgIA, Vc1.1.
Current Pharmaceutical Design
Title:Alpha9Alpha10 Nicotinic Acetylcholine Receptors as Target for the Treatment of Chronic Pain
Volume: 20 Issue: 38
Author(s): Alessandra Del Bufalo, Alfredo Cesario, Gianluca Salinaro, Massimo Fini and Patrizia Russo
Affiliation:
Keywords: Chronic pain, α9α10 nAChR, α-conotoxins, pathophysiology, RgIA, Vc1.1.
Abstract: Chronic pain is a widespread healthcare problem affecting not only the patient but in many ways all the society. Chronic pain is a disease itself that endures for a long period of time and it is resistant to the majority of medical treatments that provide modest improvements in pain and minimum improvements in physical and emotional functioning. More co-existing chronic pain conditions may be present in the same individual (patient). The α9α10 nicotinic acetylcholine receptor (nAChR) may be a potential target in the pathophysiology of chronic pain, as well in the development of breast and lung cancers. α-conotoxins (α-CNT) are small peptides used offensively by carnivorous marine snails known as Conus that target nAChR. Among α-CNT there are potent and selective antagonists of α9α10 nAChR such as RgIA and Vc1.1 that produces both acute and long lasting analgesia. Moreover, these peptides accelerate the recovery of nerve function after injury, likely through immune/inflammatory-mediated mechanisms. We review the background, findings, implications and problems in using compounds that act on α9α10 nAChR.
Export Options
About this article
Cite this article as:
Bufalo Del Alessandra, Cesario Alfredo, Salinaro Gianluca, Fini Massimo and Russo Patrizia, Alpha9Alpha10 Nicotinic Acetylcholine Receptors as Target for the Treatment of Chronic Pain, Current Pharmaceutical Design 2014; 20 (38) . https://dx.doi.org/10.2174/1381612820666140314150634
DOI https://dx.doi.org/10.2174/1381612820666140314150634 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Innovative Therapeutic Potential of Cannabinoid Receptors as Targets in Alzheimer’s Disease and Less Well-Known Diseases
Current Medicinal Chemistry Tyrosine Kinase Inhibitors (TKIs) in Lung Cancer Treatment: A Comprehensive Analysis
Current Cancer Drug Targets Apoptotic Potency of Angiostatic Compounds in the Treatment of Cancer
Current Pharmaceutical Biotechnology New Perspectives in Glioma Immunotherapy
Current Pharmaceutical Design Clinical Applications of Choline PET/CT in Brain Tumors
Current Pharmaceutical Design Recent Advances of Natural and Synthetic β-Carbolines as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Metabolism and Distribution of Novel Tumor Targeting Drugs In Vivo
Current Drug Metabolism Methodological Issues of Clinical Research with EGFR Inhibitors
Current Cancer Therapy Reviews Recent Advances in the Chemistry and Synthesis of Thienopyrazine, Pyrrolopyrazine and Furopyrazine Derivatives
Current Organic Chemistry Radiation-Induced Stress Proteins - the Role of Heat Shock Proteins (HSP) in Anti- Tumor Responses
Current Medicinal Chemistry Thyroid Ultrasound and Other Imaging Procedures in the Pediatric Age
Current Pediatric Reviews Identification of Disease-Relevant Genes for Molecularly-Targeted Drug Discovery
Current Cancer Drug Targets Natural Hydrogels Applied in Photodynamic Therapy
Current Medicinal Chemistry Towards Isozyme-Selective HDAC Inhibitors For Interrogating Disease
Current Topics in Medicinal Chemistry Anticancer Activities and Mechanisms of Bisdioxopiperazine Compounds Probimane and MST-16
Anti-Cancer Agents in Medicinal Chemistry The Emerging Role of the Hippo Pathway in Lung Cancers: Clinical Implications
Current Drug Targets The cytotoxic effect of GW843682X on nasopharyngeal carcinoma
Anti-Cancer Agents in Medicinal Chemistry Linc01638 Promotes Tumorigenesis in HER2+ Breast Cancer
Current Cancer Drug Targets Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery Differential Regulation of microRNAs in Patients with Ischemic Stroke
Current Neurovascular Research